USAN Council's statement on the use of USAN as domain names is that a name published by the United States Adopted Names (USAN) Program in the USP Dictionary of USAN and International Nonproprietary Names, and on the United States Adopted Names website shall be the effective equivalent of an intellectual property right for the relevant entities.
Visit United States Adopted Names FAQ to learn more.
Comments or protests should be addressed to Stephanie Shubat, USAN program director, American Medical Association, 330 North Wabash Ave., Suite 39300, Chicago, Illinois 60611, or via email: [email protected].
In order to ensure your "under consideration" USAN domain name is available, you should consider purchasing the .com, .net and .org domain names of the USAN under consideration. The optimal time to do this is when you receive the letter from the USAN Program informing you of the USAN Council's naming decision.
The following names for the drugs described are "under consideration" by the USAN Council:
December 2023
Bempikibart: Treatment of autoimmune disorders
Cabamiquine: Treatment and prevention of malaria
Camlipixant: Treatment of chronic cough and pruritis (itch)
Casdozokitug: Antineoplastic
Dalzanemdor: Treatment of cognitive impairment in neurodegenerative disorders
Eciskafusp alfa: Antineoplastic
Esepapogene zalarnarepvec: Treatment of HPV and an antineoplastic
Floretyrosine F18: For investigating brain tumors and gliomas with positron emission tomography (PET)
Givinostat: Treatment of Duchenne Muscular Dystrophy (DMD) and Polycythemia Vera (PV)
Lepzacitinib: Treatment of atopic dermatitis
Misetionamide: Treatment of pancreatic cancer
Nadravaleucel: Antineoplastic
Ninsipapogene sibarnarepvec: Treatment of HPV and antineoplastic
Onfasprodil: Treatment of depression
Sitocabnagene loxiveluecel: Antineoplastic
Tidagixagene derxeparvovec: Treatment of patients with Giant Axonal Neuropathy (GAN)
Tildacerfont: Treatment of congenital adrenal hyperplasia
November 2023
Acoltremon: Treatment of dry eye disease (DED)
Anumigilimab: Treatment of Hidradenitis Suppurativa (HS)
Bemdaneprocel: Treatment of Parkinson’s Disease (PD)
Certepetide: Oncology, enhances penetration of anti-tumor agents into tumors
Devextinetug: Treatment of methamphetamine (METH) abuse and addiction
Dordaviprone: Antineoplastic
Etimupepimut: Antineoplastic
Imsapepimut: Antineoplastic
Ompenaclid: Treatment of relapsed/refractory colorectal cancer
Pociredir: Treatment of sickle cell disease (SCD)
Razpipadon: Treatment of apathy associated with dementia of the Alzheimer's type
Rilvegostomig: Antineoplastic
Selvigaltin: Treatment of liver disease and cancer
Tulisokibart: Treatment of Crohn’s disease, ulcerative colitis, and scleroderma-associated interstitial lung disease
Volenrelaxin: To improve cardiovascular, renal and pulmonary functions in patients with heart failure, kidney disease and/or other metabolic dysfunctions
October 2023
Bempikibart: Treatment of autoimmune disorders
Cabamiquine: Treatment and prevention of malaria
Camlipixant: Treatment of chronic cough and pruritis (itch)
Casdizokitug: Antineoplastic
Dalzanemdor: Treatment of cognitive impairment in neurodegenerative disorders
Eciskafusp alfa: Antineoplastic
Esepapogene zalernarepvec: Treatment of HPV and an antineoplastic
Floretyrosine f18: For investigating brain tumors and gliomas with positron emission tomography (PET)
Givinostat: Treatment of Duchenne Muscular Dystrophy (DMD) and Polycythemia Vera (PV)
Lepzacitinib: Treatment of atopic dermatitis
Misetionamide: Treatment of pancreatic cancer
Nadravaleucel: Antineoplastic
Ninsipapogene sibarnarepvec: Treatment of HPV and antineoplastic
Onfasprodil: Treatment of depression
Pegsebrenatide: Treatment of Parkinson’s disease and Alzheimer’s disease
Sitocabtagene loxiveleucel: Antineoplastic
Tildacerfont: Treatment of congenital adrenal hyperplasia
Tidagixagene derxeparvovec: Treatment of patients with Giant Axonal Neuropathy (GAN)
September 2023
Acoltremon: Treatment of dry eye disease (DED)
Anumigilimab: Treatment of Hidradenitis Suppurativa (HS)
Bemdaneprocel: Treatment of Parkinson’s Disease (PD)
Certepitide: Oncology, enhances penetration of anti-tumor agents into tumors
Devextinetug: Treatment of methamphetamine (METH) abuse and addiction
Dordaviprone: Antineoplastic
Etimupepimut: Antineoplastic
Ompenaclid: Treatment of relapsed/refractory colorectal cancer
Pociredir: Treatment of sickle cell disease (SCD)
Razpipadon: Treatment of apathy associated with dementia of the Alzheimer's type
Rilvegostomig: Antineoplastic
Selvigaltin: Treatment of liver disease and cancer
Tulisokibart: Treatment of Crohn’s disease, ulcerative colitis, and scleroderma-associated interstitial lung disease
Volenrelaxin: To improve cardiovascular, renal and pulmonary functions in patients with heart failure, kidney disease and/or other metabolic dysfunctions